Macartney E. Welborn

Macartney Welborn practices at Sagis Diagnostics - Houston (Directors Row) in Houston, Texas.

Macartney Welborn's NPI, 1285298471, was assigned on April 24, 2019. Macartney Welborn graduated from McGovern Medical School in 2019. Macartney Welborn holds Texas license V1918.

Macartney Welborn's primary practice is Sagis Diagnostics - Houston (Directors Row), at 4131 Directors Row, Houston, TX 77092. The practice phone is (877) 697-2447.

Macartney Welborn's primary practice is Sagis Diagnostics - Houston (Directors Row) in Houston, Texas. The medical group on file is Sagis Diagnostics. Dmand AI also links Macartney Welborn to 4 more group practices and clinics and 4 medical groups, each named with a free account. Macartney Welborn's employer is on file too: a clinical lab.

Dmand AI tracks the electronic health record (EHR) system at each site where Macartney Welborn practices, 5 sites in all. Vendor and product names are available with a free account.

Dermatology is Macartney Welborn's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Macartney Welborn is board certified in dermatology by the American Board of Dermatology. Dmand AI has Macartney Welborn's licenses on file in 15 states: Texas, South Dakota, Colorado, Florida, New Jersey, Illinois, North Dakota, Nebraska, Arizona, Louisiana, Massachusetts, Maryland, Minnesota, North Carolina and South Carolina.

Dmand AI lists benign or precancerous skin growths among the conditions Macartney Welborn treats.

CMS data shows 34 Medicare services from Macartney Welborn across 2 procedure codes in 2024, for 66 Medicare patients. Medicare paid $1,427 for them. Every service was in an office.

CMS counts 66 Medicare patients who saw Macartney Welborn in 2024. The largest group is 65 to 74, with 32 patients. 71% of them have high blood pressure, and 70% have high cholesterol. Their average risk score is 1.13, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Macartney Welborn's median patient age at 63, with 52% women.

In 2024, Macartney Welborn wrote 44 Medicare Part D claims for 24 patients. 89% of them were for generic drugs. They cover 7 drugs, with $3,621 in total drug cost. In 2022, CMS named 83 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 48 out of 100 for Macartney Welborn for performance year 2024, reported through an alternative payment model (APM). Macartney Welborn accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 72 procedures of removal of skin lesions by Macartney Welborn, more than 74% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 16 papers to Macartney Welborn, published from 2018 to 2024. 2023 was the busiest year, with 3. The most frequent topics are Antibodies, Monoclonal, Humanized, Skin Neoplasms and Ipilimumab. Macartney Welborn has published most often in J Cutan Pathol. Macartney Welborn's most frequent co-authors are Kiran Motaparthi, MD, Anisha Patel, MD and Anisha B. Patel, MD.

CMS Open Payments shows 30 general payments to Macartney Welborn from 13 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 97% of the total. Janssen Pharmaceuticals, Inc paid the most, $364.

Macartney Welborn graduated from McGovern Medical School in 2019.

Macartney Welborn is in network with 15 carriers, including Aetna, Elevance and United Healthcare. HMO plans come from the most carriers, 10. Check the plan with the practice before a visit.